[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200509379B - Memantine oral dosage forms - Google Patents

Memantine oral dosage forms

Info

Publication number
ZA200509379B
ZA200509379B ZA200509379A ZA200509379A ZA200509379B ZA 200509379 B ZA200509379 B ZA 200509379B ZA 200509379 A ZA200509379 A ZA 200509379A ZA 200509379 A ZA200509379 A ZA 200509379A ZA 200509379 B ZA200509379 B ZA 200509379B
Authority
ZA
South Africa
Prior art keywords
dosage forms
oral dosage
memantine oral
memantine
forms
Prior art date
Application number
ZA200509379A
Other languages
English (en)
Inventor
Bruce A Firestone
Janet K Cheetham
Teresa H Kuan
J Abraham M Espiritu
Zanden John J Vander
Kurjan Richard
Chang Chin-Ming
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA200509379B publication Critical patent/ZA200509379B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200509379A 2003-06-16 2005-11-17 Memantine oral dosage forms ZA200509379B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16

Publications (1)

Publication Number Publication Date
ZA200509379B true ZA200509379B (en) 2006-11-29

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509379A ZA200509379B (en) 2003-06-16 2005-11-17 Memantine oral dosage forms

Country Status (16)

Country Link
US (2) US20040254251A1 (xx)
EP (1) EP1631273A1 (xx)
JP (1) JP2006527774A (xx)
KR (1) KR20060033727A (xx)
CN (1) CN1805737A (xx)
AU (1) AU2004249151A1 (xx)
BR (1) BRPI0411451A (xx)
CA (1) CA2529535A1 (xx)
IL (1) IL172233A0 (xx)
MX (1) MXPA05012810A (xx)
NO (1) NO20055880L (xx)
PL (1) PL378902A1 (xx)
RU (1) RU2006101225A (xx)
TW (1) TW200524639A (xx)
WO (1) WO2004112768A1 (xx)
ZA (1) ZA200509379B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
EA011290B1 (ru) * 2004-06-17 2009-02-27 Мерц Фарма Гмбх Унд Ко. Кгаа Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
AU2005309601A1 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
WO2007095424A1 (en) * 2006-02-10 2007-08-23 Janssen Pharmaceutica N.V. Novel tricyclic dihydropyrazines as potassium channel openers
US20090176736A1 (en) * 2006-04-20 2009-07-09 Katsumi Dohura Pharmaceutical composition for conformational diseases
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
BRPI0718437A2 (pt) * 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
EP2211836A2 (en) 2007-10-10 2010-08-04 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9827200B2 (en) * 2012-04-24 2017-11-28 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
JP2006527774A (ja) 2006-12-07
AU2004249151A1 (en) 2004-12-29
WO2004112768A1 (en) 2004-12-29
PL378902A1 (pl) 2006-05-29
CA2529535A1 (en) 2004-12-29
NO20055880L (no) 2005-12-28
BRPI0411451A (pt) 2006-07-18
KR20060033727A (ko) 2006-04-19
RU2006101225A (ru) 2006-06-10
US20060251717A1 (en) 2006-11-09
CN1805737A (zh) 2006-07-19
IL172233A0 (en) 2006-04-10
EP1631273A1 (en) 2006-03-08
US20040254251A1 (en) 2004-12-16
MXPA05012810A (es) 2006-02-13
TW200524639A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
IL172233A0 (en) Memantine oral dosage forms
GB0322284D0 (en) Medicament dispenser
GB0217225D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
HK1107768A1 (en) Solid drug for oral use
IL174342A0 (en) Chronotherapeutic dosage forms
GB0324886D0 (en) Medicinal compounds
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
GB0302671D0 (en) Pharmaceutical formulations
GB0303396D0 (en) Medicinal compounds
AU2003238670A8 (en) Fast disintegrating oral dosage forms
GB0209668D0 (en) Oral devices
IL172824A0 (en) Pharmaceutical formulations
GB0302672D0 (en) Pharmaceutical formulations
GB0328490D0 (en) Medicinal compounds
HK1092715A1 (en) Melt-formulated, multi-particulate oral dosage form
GB0325383D0 (en) Oral formulations
GB0206505D0 (en) Pharmaceutical combination
GB0316341D0 (en) Pharmaceutical formulations
PL373409A1 (en) Pharmaceutical combination
ZA200600560B (en) Combined doses
GB0315019D0 (en) Dosage form
GB0316335D0 (en) Pharmaceutical formulations
GB0220451D0 (en) Pharmaceutical use
GB0308469D0 (en) Pharmaceutical combination